- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics | 1.151 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
15-Dec-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 25.11.25 | Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up | 4 | RTTNews | ||
| 25.11.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | 1.365 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| 14.11.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shareholders Approve Business Combination with NeuroX | 3.148 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-Nov-2025 / 18:20 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.10.25 | Relief Therapeutics Shares Surge On Positive Results Of RLF-OD032 Bioequivalent Study | 14 | RTTNews | ||
| 29.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | 1.278 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-Oct-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 24.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Convenes Extraordinary General Meeting | 1.766 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Convenes Extraordinary General Meeting
24-Oct-2025 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
| 08.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination | 1.876 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08-Oct-2025... ► Artikel lesen | |
| 14.08.25 | Relief Therapeutics erzielt leicht weniger Verlust im ersten Halbjahr | 841 | Moneycab | Genf - Das Biotechunternehmen Relief Therapeutics hat im ersten Halbjahr 2025 leicht weniger Verlust geschrieben. Die liquiden Mittel erhöhten sich gegenüber Ende 2024. Die gesamten Einnahmen verringerten... ► Artikel lesen | |
| 14.08.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Half-Year Report | 1.755 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Publishes 2025 Half-Year Report
14-Aug-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 11.08.25 | Relief Therapeutics Holding SA: Relief Therapeutics Advances Publication of 2025 Half-Year Report | 625 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
| 29.07.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze | 2.052 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29-Jul-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 20.06.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | 4.581 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 12.06.25 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Results of Annual General Meeting | 675 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces... ► Artikel lesen | |
| 22.05.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | 5.169 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
| 15.05.25 | Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | 745 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes... ► Artikel lesen | |
| 10.04.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update | 1.707 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Annual Results
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10-Apr-2025 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
| 06.03.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion | 6.629 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06-March-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 11.02.25 | Relief Therapeutics Holding SA: Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 | 914 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Patent
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11.02.2025 / 07:00 CET/CEST
Relief... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,005 | +900,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen |
Das Unternehmen RELIEF THERAPEUTICS HOLDING AG ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELIEF THERAPEUTICS HOLDING AG ADR finden Sie auf Wallstreet Online.